Literature DB >> 14636781

Human prion diseases: epidemiology and integrated risk assessment.

Markus Glatzel1, Peter M Ott, Thomas Linder, Jan O Gebbers, Arnold Gmür, Werner Wüst, Gerhard Huber, Holger Moch, Michael Podvinec, Bernhard Stamm, Adriano Aguzzi.   

Abstract

Human prion diseases are devastating and incurable, but are very rare. Fears that the bovine spongiform encephalopathy epizootic would lead to a large epidemic of its presumed human counterpart, variant Creutzfeldt-Jakob disease (vCJD), have not been realised. Yet a feeling of uncertainty prevails in the general public and in the biomedical world. The lack of data on the prevalence of asymptomatic carriers of vCJD compounds this uncertainty. In addition to this problem, Switzerland is currently faced with another issue of major public concern: a recent rise in the incidence of CJD. Here we examine the plausibility of several scenarios that may account for the increase in CJD incidence, including ascertainment bias due to improved reporting of CJD, iatrogenic transmission, and transmission of a prion zoonosis. In addition, we present the design and current status of a Swiss population-wide study of subclinical vCJD prevalence.

Entities:  

Mesh:

Year:  2003        PMID: 14636781     DOI: 10.1016/s1474-4422(03)00588-x

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  18 in total

1.  Why aren't we more ahead? The risk of variant Creutzfeldt-Jakob disease from eating bovine spongiform encephalopathy-infected foods: still undetermined.

Authors:  Miquel Porta; Alfredo Morabia
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

2.  Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies.

Authors:  Gaetano Donofrio; Frank L Heppner; Magdalini Polymenidou; Christine Musahl; Adriano Aguzzi
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Binding of bovine T194A PrP(C) by PrP(Sc)-specific antibodies: potential implications for immunotherapy of familial prion diseases.

Authors:  Claudia A Madampage; Pekka Määttänen; Kristen Marciniuk; Robert Brownlie; Olga Andrievskaia; Andrew Potter; Neil R Cashman; Jeremy S Lee; Scott Napper
Journal:  Prion       Date:  2013-05-31       Impact factor: 3.931

4.  A study of clinical profile, radiological and electroencephalographic characteristics of suspected Creutzfeldt-Jakob disease in a tertiary care centre in South India.

Authors:  Rohan R Mahale; Mahendra Javali; Anish Mehta; Suryanarayana Sharma; Purushottam Acharya; Rangasetty Srinivasa
Journal:  J Neurosci Rural Pract       Date:  2015-01

5.  The M129V polymorphism of codon 129 in the prion gene (PRNP) in the Danish population.

Authors:  Henrik Dyrbye; Helle Broholm; Morten Hanefeld Dziegiel; Henning Laursen
Journal:  Eur J Epidemiol       Date:  2007-11-07       Impact factor: 8.082

6.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

7.  Preclinical deposition of pathological prion protein in muscle of experimentally infected primates.

Authors:  Susanne Krasemann; Melanie Neumann; Markus Geissen; Walter Bodemer; Franz-Josef Kaup; Walter Schulz-Schaeffer; Nathalie Morel; Adriano Aguzzi; Markus Glatzel
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

8.  Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.

Authors:  Tehila Mayer-Sonnenfeld; Dana Avrahami; Yael Friedman-Levi; Ruth Gabizon
Journal:  Cell Mol Neurobiol       Date:  2008-03-19       Impact factor: 5.046

9.  Detection of proteinase K resistant proteins in the urine of patients with Creutzfeldt-Jakob and other neurodegenerative diseases.

Authors:  Reza Dabaghian; Inga Zerr; Uta Heinemann; Gianluigi Zanusso
Journal:  Prion       Date:  2008 Oct-Dec       Impact factor: 3.931

10.  Movement disorders reveal Creutzfeldt-Jakob disease.

Authors:  Michael Weller; Adriano Aguzzi
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.